The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy
Background Molecular imaging is pivotal in staging and response assessment of children with neuroblastoma (NB). [ 123 I]-metaiodobenzylguanidine (mIBG) is the standard imaging method; however, it is characterised by low spatial resolution, time-consuming acquisition procedures and difficult interpre...
Saved in:
Published in | European journal of nuclear medicine and molecular imaging Vol. 51; no. 3; pp. 756 - 767 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.02.2024
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background
Molecular imaging is pivotal in staging and response assessment of children with neuroblastoma (NB). [
123
I]-metaiodobenzylguanidine (mIBG) is the standard imaging method; however, it is characterised by low spatial resolution, time-consuming acquisition procedures and difficult interpretation. Many PET catecholaminergic radiotracers have been proposed as a replacement for [
123
I]-mIBG, however they have not yet made it into clinical practice. We aimed to review the available literature comparing head-to-head [
123
I]-mIBG with the most common PET catecholaminergic radiopharmaceuticals.
Methods
We searched the PubMed database for studies performing a head-to-head comparison between [
123
I]-mIBG and PET radiopharmaceuticals including meta-hydroxyephedrine ([
11
C]C-HED),
18
F-18F-3,4-dihydroxyphenylalanine ([
18
F]DOPA) [
124
I]mIBG and
Meta
-[18F]fluorobenzylguanidine ([
18
F]mFBG). Review articles, preclinical studies, small case series (< 5 subjects), case reports, and articles not in English were excluded. From each study, the following characteristics were extracted: bibliographic information, technical parameters, and the sensitivity of the procedure according to a patient-based analysis (PBA) and a lesion-based analysis (LBA).
Results
Ten studies were selected: two regarding [
11
C]C-HED, four [
18
F]DOPA, one [
124
I]mIBG, and three [
18
F]mFBG. These studies included 181 patients (range 5–46). For the PBA, the superiority of the PET method was reported in two out of ten studies (both using [
18
F]DOPA). For LBA, PET detected significantly more lesions than scintigraphy in seven out of ten studies.
Conclusions
PET/CT using catecholaminergic tracers shows superior diagnostic performance than mIBG scintigraphy. However, it is still unknown if such superiority can influence clinical decision-making. Nonetheless, the PET examination appears promising for clinical practice as it offers faster image acquisition, less need for sedation, and a single-day examination. |
---|---|
AbstractList | Molecular imaging is pivotal in staging and response assessment of children with neuroblastoma (NB). [
I]-metaiodobenzylguanidine (mIBG) is the standard imaging method; however, it is characterised by low spatial resolution, time-consuming acquisition procedures and difficult interpretation. Many PET catecholaminergic radiotracers have been proposed as a replacement for [
I]-mIBG, however they have not yet made it into clinical practice. We aimed to review the available literature comparing head-to-head [
I]-mIBG with the most common PET catecholaminergic radiopharmaceuticals.
We searched the PubMed database for studies performing a head-to-head comparison between [
I]-mIBG and PET radiopharmaceuticals including meta-hydroxyephedrine ([
C]C-HED),
F-18F-3,4-dihydroxyphenylalanine ([
F]DOPA) [
I]mIBG and Meta-[18F]fluorobenzylguanidine ([
F]mFBG). Review articles, preclinical studies, small case series (< 5 subjects), case reports, and articles not in English were excluded. From each study, the following characteristics were extracted: bibliographic information, technical parameters, and the sensitivity of the procedure according to a patient-based analysis (PBA) and a lesion-based analysis (LBA).
Ten studies were selected: two regarding [
C]C-HED, four [
F]DOPA, one [
I]mIBG, and three [
F]mFBG. These studies included 181 patients (range 5-46). For the PBA, the superiority of the PET method was reported in two out of ten studies (both using [
F]DOPA). For LBA, PET detected significantly more lesions than scintigraphy in seven out of ten studies.
PET/CT using catecholaminergic tracers shows superior diagnostic performance than mIBG scintigraphy. However, it is still unknown if such superiority can influence clinical decision-making. Nonetheless, the PET examination appears promising for clinical practice as it offers faster image acquisition, less need for sedation, and a single-day examination. BACKGROUNDMolecular imaging is pivotal in staging and response assessment of children with neuroblastoma (NB). [123I]-metaiodobenzylguanidine (mIBG) is the standard imaging method; however, it is characterised by low spatial resolution, time-consuming acquisition procedures and difficult interpretation. Many PET catecholaminergic radiotracers have been proposed as a replacement for [123I]-mIBG, however they have not yet made it into clinical practice. We aimed to review the available literature comparing head-to-head [123I]-mIBG with the most common PET catecholaminergic radiopharmaceuticals.METHODSWe searched the PubMed database for studies performing a head-to-head comparison between [123I]-mIBG and PET radiopharmaceuticals including meta-hydroxyephedrine ([11C]C-HED), 18F-18F-3,4-dihydroxyphenylalanine ([18F]DOPA) [124I]mIBG and Meta-[18F]fluorobenzylguanidine ([18F]mFBG). Review articles, preclinical studies, small case series (< 5 subjects), case reports, and articles not in English were excluded. From each study, the following characteristics were extracted: bibliographic information, technical parameters, and the sensitivity of the procedure according to a patient-based analysis (PBA) and a lesion-based analysis (LBA).RESULTSTen studies were selected: two regarding [11C]C-HED, four [18F]DOPA, one [124I]mIBG, and three [18F]mFBG. These studies included 181 patients (range 5-46). For the PBA, the superiority of the PET method was reported in two out of ten studies (both using [18F]DOPA). For LBA, PET detected significantly more lesions than scintigraphy in seven out of ten studies.CONCLUSIONSPET/CT using catecholaminergic tracers shows superior diagnostic performance than mIBG scintigraphy. However, it is still unknown if such superiority can influence clinical decision-making. Nonetheless, the PET examination appears promising for clinical practice as it offers faster image acquisition, less need for sedation, and a single-day examination. Abstract Background Molecular imaging is pivotal in staging and response assessment of children with neuroblastoma (NB). [ 123 I]-metaiodobenzylguanidine (mIBG) is the standard imaging method; however, it is characterised by low spatial resolution, time-consuming acquisition procedures and difficult interpretation. Many PET catecholaminergic radiotracers have been proposed as a replacement for [ 123 I]-mIBG, however they have not yet made it into clinical practice. We aimed to review the available literature comparing head-to-head [ 123 I]-mIBG with the most common PET catecholaminergic radiopharmaceuticals. Methods We searched the PubMed database for studies performing a head-to-head comparison between [ 123 I]-mIBG and PET radiopharmaceuticals including meta-hydroxyephedrine ([ 11 C]C-HED), 18 F-18F-3,4-dihydroxyphenylalanine ([ 18 F]DOPA) [ 124 I]mIBG and Meta -[18F]fluorobenzylguanidine ([ 18 F]mFBG). Review articles, preclinical studies, small case series (< 5 subjects), case reports, and articles not in English were excluded. From each study, the following characteristics were extracted: bibliographic information, technical parameters, and the sensitivity of the procedure according to a patient-based analysis (PBA) and a lesion-based analysis (LBA). Results Ten studies were selected: two regarding [ 11 C]C-HED, four [ 18 F]DOPA, one [ 124 I]mIBG, and three [ 18 F]mFBG. These studies included 181 patients (range 5–46). For the PBA, the superiority of the PET method was reported in two out of ten studies (both using [ 18 F]DOPA). For LBA, PET detected significantly more lesions than scintigraphy in seven out of ten studies. Conclusions PET/CT using catecholaminergic tracers shows superior diagnostic performance than mIBG scintigraphy. However, it is still unknown if such superiority can influence clinical decision-making. Nonetheless, the PET examination appears promising for clinical practice as it offers faster image acquisition, less need for sedation, and a single-day examination. Background Molecular imaging is pivotal in staging and response assessment of children with neuroblastoma (NB). [ 123 I]-metaiodobenzylguanidine (mIBG) is the standard imaging method; however, it is characterised by low spatial resolution, time-consuming acquisition procedures and difficult interpretation. Many PET catecholaminergic radiotracers have been proposed as a replacement for [ 123 I]-mIBG, however they have not yet made it into clinical practice. We aimed to review the available literature comparing head-to-head [ 123 I]-mIBG with the most common PET catecholaminergic radiopharmaceuticals. Methods We searched the PubMed database for studies performing a head-to-head comparison between [ 123 I]-mIBG and PET radiopharmaceuticals including meta-hydroxyephedrine ([ 11 C]C-HED), 18 F-18F-3,4-dihydroxyphenylalanine ([ 18 F]DOPA) [ 124 I]mIBG and Meta -[18F]fluorobenzylguanidine ([ 18 F]mFBG). Review articles, preclinical studies, small case series (< 5 subjects), case reports, and articles not in English were excluded. From each study, the following characteristics were extracted: bibliographic information, technical parameters, and the sensitivity of the procedure according to a patient-based analysis (PBA) and a lesion-based analysis (LBA). Results Ten studies were selected: two regarding [ 11 C]C-HED, four [ 18 F]DOPA, one [ 124 I]mIBG, and three [ 18 F]mFBG. These studies included 181 patients (range 5–46). For the PBA, the superiority of the PET method was reported in two out of ten studies (both using [ 18 F]DOPA). For LBA, PET detected significantly more lesions than scintigraphy in seven out of ten studies. Conclusions PET/CT using catecholaminergic tracers shows superior diagnostic performance than mIBG scintigraphy. However, it is still unknown if such superiority can influence clinical decision-making. Nonetheless, the PET examination appears promising for clinical practice as it offers faster image acquisition, less need for sedation, and a single-day examination. |
Author | Fiz, Francesco de Keizer, Bart Piccardo, Arnoldo Lopci, Egesta Biassoni, Lorenzo Nadel, Helen De Palma, Diego Roca Bielsa, Isabel Santos, Ana Isabel Massollo, Michela Treglia, Giorgio Cecchin, Diego Vali, Reza Jehanno, Nina Shulkin, Barry Bar-Sever, Zvi Kurch, Lars Borgwardt, Lise Bottoni, Gianluca Zucchetta, Pietro |
Author_xml | – sequence: 1 givenname: Arnoldo orcidid: 0000-0002-6779-1471 surname: Piccardo fullname: Piccardo, Arnoldo email: arnoldo.piccardo@galliera.it organization: Department of Nuclear Medicine, E.O. “Ospedali Galliera” – sequence: 2 givenname: Giorgio surname: Treglia fullname: Treglia, Giorgio organization: Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Faculty of Biology and Medicine, University of Lausanne, Faculty of Biomedical Sciences, Università Della Svizzera Italiana – sequence: 3 givenname: Francesco surname: Fiz fullname: Fiz, Francesco organization: Department of Nuclear Medicine, E.O. “Ospedali Galliera”, Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital – sequence: 4 givenname: Zvi surname: Bar-Sever fullname: Bar-Sever, Zvi organization: Department of Nuclear Medicine, Schneider Children’s Medical Center, Tel Aviv University – sequence: 5 givenname: Gianluca surname: Bottoni fullname: Bottoni, Gianluca organization: Department of Nuclear Medicine, E.O. “Ospedali Galliera” – sequence: 6 givenname: Lorenzo surname: Biassoni fullname: Biassoni, Lorenzo organization: Great Ormond Street Hospital for Children, NHS Foundation Trust – sequence: 7 givenname: Lise surname: Borgwardt fullname: Borgwardt, Lise organization: Rigshospitalet, University of Copenhagen – sequence: 8 givenname: Bart surname: de Keizer fullname: de Keizer, Bart organization: Department of Nuclear Medicine and Radiology, University Medical Center Utrecht – sequence: 9 givenname: Nina surname: Jehanno fullname: Jehanno, Nina organization: Department of Nuclear Medicine, Institut Curie Paris – sequence: 10 givenname: Egesta surname: Lopci fullname: Lopci, Egesta organization: Nuclear Medicine Unit, IRCCS-Humanitas Research Hospital – sequence: 11 givenname: Lars surname: Kurch fullname: Kurch, Lars organization: Department of Nuclear Medicine, University Hospital Leipzig – sequence: 12 givenname: Michela surname: Massollo fullname: Massollo, Michela organization: Department of Nuclear Medicine, E.O. “Ospedali Galliera” – sequence: 13 givenname: Helen surname: Nadel fullname: Nadel, Helen organization: Department of Pediatric Nuclear Medicine, Lucile Packard Children’s Hospital of Stanford (CA) – sequence: 14 givenname: Isabel surname: Roca Bielsa fullname: Roca Bielsa, Isabel organization: Universitat Autònoma de Barcelona – sequence: 15 givenname: Barry surname: Shulkin fullname: Shulkin, Barry organization: St Jude Children’s Research Hospital – sequence: 16 givenname: Reza surname: Vali fullname: Vali, Reza organization: Division of Nuclear Medicine, Department of Diagnostic Imaging, The Hospital for Sick Children of Toronto – sequence: 17 givenname: Diego surname: De Palma fullname: De Palma, Diego organization: Nuclear Medicine Unit, Ospedale Di Circolo of Varese – sequence: 18 givenname: Diego surname: Cecchin fullname: Cecchin, Diego organization: Nuclear Medicine Unit, Department of Medicine - DIMED, University Hospital of Padova – sequence: 19 givenname: Ana Isabel surname: Santos fullname: Santos, Ana Isabel organization: Department of Nuclear Medicine, Hospital Garcia de Orta – sequence: 20 givenname: Pietro surname: Zucchetta fullname: Zucchetta, Pietro organization: Nuclear Medicine Unit, Department of Medicine - DIMED, University Hospital of Padova |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37962616$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kctu1TAQhi1URC_wAiyQJTZsUnxJ7HhZqlIqVcDisLYmzuTEVWIfbIfqPAcvTMopRWLBxmNpvvlnpO-UHIUYkJDXnJ1zxvT7zJhoTMWErJiqW1WZZ-SEK24qzVpz9PTX7Jic5nzHGG9Fa16QY6mNEoqrE_JzMyLFH77H4LDqIGNPU5yQxoE6KOjGOMHsA6atd_Tr1YaWBA5Tpj7Qz7ik2E2QS5zhnF7QvM8FZygrmtZQvKcQegp0ROirEquHSl2cd5B8joHe-zLS-ebDNc3Oh-K3CXbj_iV5PsCU8dVjPSPfPl5tLj9Vt1-uby4vbitXc1OqQbPeDRqNANXUg-66QTB0vJXAtW6YFHJ9mBiM6lnXgJCuR1VL6LlToECekXeH3F2K3xfMxc4-O5wmCBiXbEXbGmOkbviKvv0HvYtLCut1VhiuRMNrJVZKHCiXYs4JB7tLfoa0t5zZB2X2oMyuyuxvZdasQ28eo5duxv5p5I-jFZAHIK-tsMX0d_d_Yn8BcoukcA |
CitedBy_id | crossref_primary_10_1097_RLU_0000000000005226 crossref_primary_10_3389_fmed_2023_1320574 crossref_primary_10_1016_j_diii_2024_04_004 crossref_primary_10_1053_j_semnuclmed_2024_03_003 crossref_primary_10_2967_jnumed_123_267256 |
Cites_doi | 10.1186/1471-2407-11-21 10.1016/j.apradiso.2014.03.026 10.1097/RLU.0000000000001984 10.1097/RLU.0000000000004185 10.1200/JCO.2014.59.4648 10.2967/jnumed.116.186833 10.1200/JCO.2007.13.8925 10.1186/s40658-016-0144-5 10.1200/JCO.2008.20.5732 10.1097/RLU.0b013e31827a0002 10.2967/jnumed.120.243139 10.1002/1096-911x(200008)35:23.0.co;2-7 10.1007/s00259-011-1938-2 10.2967/jnumed.108.060467 10.3390/jpm11040270 10.7326/0003-4819-155-8-201110180-00009 10.1007/s13139-022-00762-6 10.1007/s00259-023-06221-4 10.1001/jama.2017.19163 10.2967/jnumed.119.232553 10.1002/14651858.CD009263.pub2 10.1007/s00259-017-3829-7 10.1097/RLU.0000000000002961 10.1053/j.semnuclmed.2016.10.007 10.2967/jnumed.117.193169 10.1097/RLU.0b013e3182485172 10.1007/s00259-022-06063-6 10.1007/s00259-018-4070-8 10.3413/Nukmed-0743-15-0 10.2967/jnumed.117.195883 10.1007/s00259-023-06160-0 10.2967/jnumed.112.102772 10.1200/jco.2014.32.15_suppl.10029 10.1002/mp.12202 10.1038/sj.bjc.660562 |
ContentType | Journal Article |
Copyright | The Author(s) 2023 2023. The Author(s). The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | C6C CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TK K9. NAPCQ 7X8 |
DOI | 10.1007/s00259-023-06486-9 |
DatabaseName | Springer_OA刊 Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Neurosciences Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Neurosciences Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: C6C name: Springer_OA刊 url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1619-7089 |
EndPage | 767 |
ExternalDocumentID | 10_1007_s00259_023_06486_9 37962616 |
Genre | Systematic Review Journal Article Review |
GroupedDBID | --- -5E -5G -BR -Y2 -~C .86 .GJ .VR 04C 06C 06D 0R~ 0VY 199 1N0 203 29G 29~ 2JN 2JY 2KM 2LR 2P1 2VQ 2~H 30V 36B 3V. 4.4 406 40D 53G 5GY 5QI 5RE 5VS 67Z 6NX 78A 7RV 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ 8UJ 95- 95. 95~ 96X AAAVM AABYN AAFGU AAHNG AAIAL AAKSU AANXM AANZL AARHV AARTL AATNV AATVU AAUYE AAWCG AAYFA AAYQN AAYTO ABBBX ABBXA ABDBF ABECU ABFGW ABFTV ABHQN ABIPD ABJNI ABJOX ABKAS ABKCH ABLJU ABMNI ABMQK ABNWP ABPLI ABPTK ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFS ACHSB ACHVE ACIGE ACIPQ ACIWK ACMDZ ACMLO ACOKC ACOMO ACPRK ACTTH ACUDM ACVWB ACWMK ADBBV ADHIR ADINQ ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEEQQ AEFIE AEFTE AEGAL AEGNC AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AEVLU AEVTX AEXYK AFAFS AFEXP AFFNX AFJLC AFKRA AFLOW AFNRJ AFQWF AFRAH AFWTZ AGAYW AGDGC AGGBP AGGDS AGJBK AGKHE AGMZJ AGQMX AGWIL AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHVUH AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARAPS ARMRJ AXYYD AZFZN B-. B0M BA0 BBNVY BDATZ BENPR BGLVJ BGNMA BHPHI BKEYQ BMSDO BPHCQ BVXVI C6C CAG CCPQU COF CSCUP DDRTE DL5 DNIVK DPUIP DU5 EAD EAP EAS EBB EBC EBD EBLON EBO EBS EBX EHN EIHBH EIOEI EJD EMB EMK EMOBN EN4 EPL EPT ESBYG ESX EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GNWQR GQ6 GQ7 GQ8 GRRUI GXS HCIFZ HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KPH LAS LK8 LLZTM M1P M4Y M7P MA- N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P62 P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS Q~Q R89 R9I RNI RNS ROL RPX RRX RSV RZK S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TH9 TSG TSK TT1 TUS U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WK8 WOW YLTOR Z45 Z7R Z7U Z7V Z7W Z7X Z7Y Z7Z Z81 Z82 Z83 Z85 Z87 Z88 Z8M Z8O Z8P Z8Q Z8R Z8S Z8T Z8U Z8V Z8W Z8Z Z91 ZMTXR ~8M AACDK AAEOY AAJBT AASML AAYZH ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU AJOOF ALIPV CGR CUY CVF ECM EIF H13 NPM AAYXX CITATION 7TK K9. 7X8 |
ID | FETCH-LOGICAL-c419t-f70dcf7e92a654f7bbf20ec183a1775032350302f96d0b5a23cde643ad1c6a6a3 |
IEDL.DBID | C6C |
ISSN | 1619-7070 |
IngestDate | Fri Aug 16 23:49:01 EDT 2024 Thu Oct 10 22:05:03 EDT 2024 Thu Sep 12 18:09:57 EDT 2024 Wed Oct 23 10:04:42 EDT 2024 Fri Jan 19 03:31:40 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Paediatric PET I]MIBG, 18F-MFBG, 11C-HED Guideline PET-CT F]F-DOPA Neuroblastoma [ Catecholamine [18F]F-DOPA [124I]MIBG, 18F-MFBG, 11C-HED |
Language | English |
License | 2023. The Author(s). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c419t-f70dcf7e92a654f7bbf20ec183a1775032350302f96d0b5a23cde643ad1c6a6a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0002-6779-1471 |
OpenAccessLink | https://doi.org/10.1007/s00259-023-06486-9 |
PMID | 37962616 |
PQID | 2916251462 |
PQPubID | 42802 |
PageCount | 12 |
ParticipantIDs | proquest_miscellaneous_2889993751 proquest_journals_2916251462 crossref_primary_10_1007_s00259_023_06486_9 pubmed_primary_37962616 springer_journals_10_1007_s00259_023_06486_9 |
PublicationCentury | 2000 |
PublicationDate | 2024-02-01 |
PublicationDateYYYYMMDD | 2024-02-01 |
PublicationDate_xml | – month: 02 year: 2024 text: 2024-02-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Berlin/Heidelberg |
PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
PublicationTitle | European journal of nuclear medicine and molecular imaging |
PublicationTitleAbbrev | Eur J Nucl Med Mol Imaging |
PublicationTitleAlternate | Eur J Nucl Med Mol Imaging |
PublicationYear | 2024 |
Publisher | Springer Berlin Heidelberg Springer Nature B.V |
Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
References | Beijst C, de Keizer B, Lam MGEH, Janssens GO, Tytgat GAM, de Jong HWAM. A phantom study: Should124I-mIBG PET/CT replace123I-mIBG SPECT/CT? Med Phys. 2017;44:1624–31. https://doi.org/10.1002/mp.12202. Franzius C, Hermann K, Weckesser M, Kopka K, Juergens KU, Vormoor J, et al. Whole-Body PET/CT with11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: Feasibility study and comparison with 123I-MIBG SPECT/CT. J Nucl Med. 2006;47:1635-42 Bleeker G, Tytgat GAM, Adam JA, Caron HN, Kremer LCM, Hooft L, et al. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. Cochrane Database Syst Rev. 29;2015:CD009263. https://doi.org/10.1002/14651858.CD009263.pub2. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. Quadas-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36. https://doi.org/10.7326/0003-4819-155-8-201110180-00009. Černý I, Prášek J, Kašpárková H. Superiority of SPECT/CT over planar 123I-mIBG images in neuroblastoma patients with impact on Curie and SIOPEN score values. Nuklearmedizin. 20165;55:151–7. https://doi.org/10.3413/Nukmed-0743-15-0. Ladenstein R, Lambert B, Pötschger U, Castellani MR, Lewington V, Bar-Sever Z, et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging. 2018;45:292–305. https://doi.org/10.1007/s00259-017-3829-7. Lopci E, Piccardo A, Nanni C, Altrinetti V, Garaventa A, Pession A, et al. 18F-DOPA PET/CT in neuroblastoma: Comparison of conventional imaging with CT/MR. Clin Nucl Med. 2012;37:e73–8. https://doi.org/10.1097/RLU.0b013e3182485172. Telli T, Lay Ergün E, Volkan Salanci B, Özgen Kiratli P. The complementary role of 68Ga-DOTATATE PET/CT in neuroblastoma. Clin Nucl Med. 2020;45:326–9.https://doi.org/10.1097/RLU.0000000000002961. Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009;27:5343–9. https://doi.org/10.1200/JCO.2008.20.5732. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015 20;33:3008–17. https://doi.org/10.1200/JCO.2014.59.4648. Piccardo A, Lopci E, Conte M, Garaventa A, Foppiani L, Altrinetti V, et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: A pilot study. Eur J Nucl Med Mol Imaging. 2012;39:57–71. https://doi.org/10.1007/s00259-011-1938-2. Borgwardt L, Brok JS, Andersen KF, Madsen J, Gillings N, Fosbøl M, et al. [18F]mFBG long axial field of view PET-CT without general anaesthesia reveals concise extension of neuroblastoma in a 9-month-old boy. Eur J Nucl Med Mol Imaging. 2023;50:2563–64. https://doi.org/10.1007/s00259-023-06160-0. YanikGAParisiMTNaranjoANadelHGelfandMJParkJRValidation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children’s Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1J Nucl Med2018595025081:CAS:528:DC%2BC1cXitFylurbF10.2967/jnumed.117.195883288873995868501 ContiMErikssonLPhysics of pure and non-pure positron emitters for PET: a review and a discussionEJNMMI Phys20163810.1186/s40658-016-0144-5272713044894854 Piccardo A, Morana G, Puntoni M, Campora S, Sorrentino S, Zucchetta P, et al. Diagnosis, treatment response, and prognosis: The role of 18F-DOPA PET/CT in children affected by neuroblastoma in comparison with 123I-mIBG scan: The first prospective study. J Nucl Med. 2020;61:367–74. https://doi.org/10.2967/jnumed.119.232553. Aboian MS, Huang SY, Hernandez-Pampaloni M, Hawkins RA, VanBrocklin HF, Huh Y, et al. 124I-MIBG PET/CT to monitor metastatic disease in children with relapsed neuroblastoma. J Nucl Med. 2021;62(1):43–7. https://doi.org/10.2967/jnumed.120.243139. Pandit-TaskarNZanzonicoPStatonKDCarrasquilloJAReidy-LagunesDLyashchenkoSBiodistribution and Dosimetry of 18 F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine MalignanciesJ Nucl Med2018591471531:CAS:528:DC%2BC1cXitFCjsL7F10.2967/jnumed.117.193169287059165750519 Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children’s oncology group study. J Clin Oncol. 2009;27:1007–13. https://doi.org/10.1200/JCO.2007.13.8925. Boubaker A, Poetschger U, Lambert B, Castellani MR, Bar-Sever Z, Oudoux A, et al. Validation of the MIBG SIOPEN scoring method in two independent high-risk neuroblastoma trials. J Clin Oncol. 2014;32. https://doi.org/10.1200/jco.2014.32.15_suppl.10029. Bar-Sever Z, Biassoni L, Shulkin B, Kong G, Hofman MS, Lopci E, et al. Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging. 2018;45:2009–24. https://doi.org/10.1007/s00259-018-4070-8. Biasotti S, Garaventa A, Villavecchia GP, Cabria M, Nantron M, De Bernardi B. False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. Med Pediatr Oncol. 2000;35:153–5. https://doi.org/10.1002/1096-911x(200008)35:23.0.co;2-7. Lu MY, Liu YL, Chang HH, Jou ST, Yang YL, Lin KH, et al. Characterization of neuroblastic tumors using 18F-FDOPA PET. J Nucl Med. 2013;54:42–9. https://doi.org/10.2967/jnumed.112.102772. Hemrom A, Arora G, Damle NA, Bal C. Comparative role of 18F-DOPA PET/CT and 131I-MIBG scintigraphy in neuroblastoma and application of curie and SIOPEN scoring systems in 18F-DOPA PET/CT. Nucl Med Mol Imaging. 2022;56:236–44. https://doi.org/10.1007/s13139-022-00762-6. Piccardo A, Lopci E, Conte M, Cabria M, Cistaro A, Garaventa A, et al. Bone and lymph node metastases from neuroblastoma detected by 18F-DOPA-PET/CT and confirmed by posttherapy 131I-MIBG but negative on diagnostic 123I-MIBG scan. Clin Nucl Med. 2014;39:e80–3. https://doi.org/10.1097/RLU.0b013e31827a0002. Pfluger T, Piccardo A. Neuroblastoma: MIBG imaging and new tracers. Semin Nucl Med. 2017;47:143–57. https://doi.org/10.1053/j.semnuclmed.2016.10.007. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Klingebiel T, et al. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer. 2011;11:21. https://doi.org/10.1186/1471-2407-11-21. Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and18F-FDG PET in neuroblastoma. J Nucl Med. 2009;50:1237–43. https://doi.org/10.2967/jnumed.108.060467. Wang P, Li T, Liu Z, Jin M, Su Y, Zhang J, et al. [18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma. Eur J Nucl Med Mol Imaging. 2023;50:3097–106. https://doi.org/10.1007/s00259-023-06221-4. Samim A, Tytgat GAM, Bleeker G, Wenker STM, Chatalic KLS, Poot AJ, et al. Nuclear medicine imaging in neuroblastoma: Current status and new developments. J Pers Med. 2021;11:270. https://doi.org/10.3390/jpm11040270. SamimABlomTPootAJWindhorstADFioccoMTolboomNCorrection to: [18F]mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot studyEur J Nucl Med Mol Imaging2023504114611571:CAS:528:DC%2BB38XjtV2ksr3E10.1007/s00259-022-06063-636504277 Mcinnes MDF, Moher D, Thombs BD, Mcgrath TA, Bossuyt PM. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies the PRISMA-DTA statement supplemental content CME Quiz at jamanetwork.com/learning. JAMA. 2018;319:388–96. https://doi.org/10.1001/jama.2017.19163. Braghirolli AMS, Waissmann W, Da Silva JB, Dos Santos GR. Production of iodine-124 and its applications in nuclear medicine. Appl Radiat Isot. 2014;90:138–48. https://doi.org/10.1016/j.apradiso.2014.03.026. Pandit-Taskar N, Modak S. Norepinephrine transporter as a target for imaging and therapy. J Nucl Med. 2017;58:39S–53S. https://doi.org/10.2967/jnumed.116.186833. FizFBiniFGabrieleEBottoniGGarrèMMarinozziFMilanaccioCVerricoAMassolloMBosioVLattuadaMRossiAPARole of dynamic parameters of 18F-DOPA PET/CT in pediatric gliomasClin Nucl Med20224751752410.1097/RLU.000000000000418535353725 Pandit-Taskar N, Zanzonico P, Staton KD, Carrasquillo JA, Reidy-Lagunes D, Lyashchenko S, et al. Biodistribution and dosimetry of 18 F-meta-fluorobenzylguanidine: A first-in-human PET/CT imaging study of patients with neuroendocrine malignancies. J Nucl Med. 2018;59:147-153. https://doi.org/10.2967/jnumed.117.193169. Liu B, Servaes S, Zhuang H. SPECT/CT MIBG imaging is crucial in the follow-up of the patients with high-risk neuroblastoma. Clin Nucl Med. 2018;43:232–8. https://doi.org/10.1097/RLU.0000000000001984. Shulkin BL, Wieland DM, Baro ME, Ungar DR, Mitchell DS, Dole MG, et al. PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med. 1996;37:16–21. Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V, et al. Criteria for evaluation of disease extent by 123 I-metaiodobenzylguanidine scans in neuroblastoma: A report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer. 2010;102:1319–26. https://doi.org/10.1038/sj.bjc.660562. N Pandit-Taskar (6486_CR22) 2018; 59 A Samim (6486_CR19) 2023; 50 F Fiz (6486_CR32) 2022; 47 6486_CR29 6486_CR28 6486_CR2 6486_CR21 6486_CR3 6486_CR20 6486_CR4 6486_CR23 6486_CR5 6486_CR6 6486_CR25 6486_CR24 6486_CR8 6486_CR27 GA Yanik (6486_CR7) 2018; 59 6486_CR9 6486_CR26 M Conti (6486_CR33) 2016; 3 6486_CR30 6486_CR1 6486_CR18 6486_CR17 6486_CR10 6486_CR31 6486_CR12 6486_CR34 6486_CR11 6486_CR14 6486_CR36 6486_CR13 6486_CR35 6486_CR16 6486_CR38 6486_CR15 6486_CR37 |
References_xml | – ident: 6486_CR1 doi: 10.1186/1471-2407-11-21 – ident: 6486_CR35 doi: 10.1016/j.apradiso.2014.03.026 – ident: 6486_CR15 – ident: 6486_CR29 doi: 10.1097/RLU.0000000000001984 – volume: 47 start-page: 517 year: 2022 ident: 6486_CR32 publication-title: Clin Nucl Med doi: 10.1097/RLU.0000000000004185 contributor: fullname: F Fiz – ident: 6486_CR2 doi: 10.1200/JCO.2014.59.4648 – ident: 6486_CR28 doi: 10.2967/jnumed.116.186833 – ident: 6486_CR3 doi: 10.1200/JCO.2007.13.8925 – volume: 3 start-page: 8 year: 2016 ident: 6486_CR33 publication-title: EJNMMI Phys doi: 10.1186/s40658-016-0144-5 contributor: fullname: M Conti – ident: 6486_CR26 doi: 10.1200/JCO.2008.20.5732 – ident: 6486_CR36 doi: 10.1097/RLU.0b013e31827a0002 – ident: 6486_CR14 – ident: 6486_CR18 doi: 10.2967/jnumed.120.243139 – ident: 6486_CR8 doi: 10.1002/1096-911x(200008)35:23.0.co;2-7 – ident: 6486_CR16 doi: 10.1007/s00259-011-1938-2 – ident: 6486_CR25 doi: 10.2967/jnumed.108.060467 – ident: 6486_CR38 doi: 10.3390/jpm11040270 – ident: 6486_CR12 doi: 10.7326/0003-4819-155-8-201110180-00009 – ident: 6486_CR17 doi: 10.1007/s13139-022-00762-6 – ident: 6486_CR21 doi: 10.1007/s00259-023-06221-4 – ident: 6486_CR11 doi: 10.1001/jama.2017.19163 – ident: 6486_CR13 doi: 10.2967/jnumed.119.232553 – ident: 6486_CR9 doi: 10.1002/14651858.CD009263.pub2 – ident: 6486_CR5 doi: 10.1007/s00259-017-3829-7 – ident: 6486_CR27 doi: 10.1097/RLU.0000000000002961 – ident: 6486_CR24 doi: 10.1053/j.semnuclmed.2016.10.007 – ident: 6486_CR37 doi: 10.2967/jnumed.117.193169 – ident: 6486_CR23 doi: 10.1097/RLU.0b013e3182485172 – volume: 50 start-page: 1146 issue: 4 year: 2023 ident: 6486_CR19 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-022-06063-6 contributor: fullname: A Samim – ident: 6486_CR4 doi: 10.1007/s00259-018-4070-8 – ident: 6486_CR30 doi: 10.3413/Nukmed-0743-15-0 – volume: 59 start-page: 502 year: 2018 ident: 6486_CR7 publication-title: J Nucl Med doi: 10.2967/jnumed.117.195883 contributor: fullname: GA Yanik – ident: 6486_CR31 doi: 10.1007/s00259-023-06160-0 – ident: 6486_CR20 doi: 10.2967/jnumed.112.102772 – volume: 59 start-page: 147 year: 2018 ident: 6486_CR22 publication-title: J Nucl Med doi: 10.2967/jnumed.117.193169 contributor: fullname: N Pandit-Taskar – ident: 6486_CR6 doi: 10.1200/jco.2014.32.15_suppl.10029 – ident: 6486_CR34 doi: 10.1002/mp.12202 – ident: 6486_CR10 doi: 10.1038/sj.bjc.660562 |
SSID | ssj0018289 |
Score | 2.4958935 |
SecondaryResourceType | review_article |
Snippet | Background
Molecular imaging is pivotal in staging and response assessment of children with neuroblastoma (NB). [
123
I]-metaiodobenzylguanidine (mIBG) is the... Molecular imaging is pivotal in staging and response assessment of children with neuroblastoma (NB). [ I]-metaiodobenzylguanidine (mIBG) is the standard... Abstract Background Molecular imaging is pivotal in staging and response assessment of children with neuroblastoma (NB). [ 123 I]-metaiodobenzylguanidine... BackgroundMolecular imaging is pivotal in staging and response assessment of children with neuroblastoma (NB). [123I]-metaiodobenzylguanidine (mIBG) is the... BACKGROUNDMolecular imaging is pivotal in staging and response assessment of children with neuroblastoma (NB). [123I]-metaiodobenzylguanidine (mIBG) is the... |
SourceID | proquest crossref pubmed springer |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 756 |
SubjectTerms | 3-Iodobenzylguanidine Cardiology Case reports Child Clinical medicine Decision making Dihydroxyphenylalanine Fluorine isotopes Humans Image acquisition Imaging Lesions Literature reviews Medical imaging Medicine Medicine & Public Health Neuroblastoma Neuroblastoma - diagnostic imaging Neuroblastoma - pathology Nuclear Medicine Oncology Orthopedics Parameter sensitivity Positron emission Positron emission tomography Positron Emission Tomography Computed Tomography - methods Positron-Emission Tomography - methods Radioactive tracers Radiology Radiopharmaceuticals Review Article Scintigraphy Spatial discrimination Spatial resolution |
Title | The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy |
URI | https://link.springer.com/article/10.1007/s00259-023-06486-9 https://www.ncbi.nlm.nih.gov/pubmed/37962616 https://www.proquest.com/docview/2916251462 https://search.proquest.com/docview/2889993751 |
Volume | 51 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1NT9wwEB1RkKpeqtIWmpaiqdQbGCVOYifH3RULRQL1ABK3aOIPaQ-bVBB-CX-44yQb1EIPvSSHWHaU58m88XieAb7HPivIlyRSlVmRFU6KMieOeWJtfGGIdK-zfXmlzm-yi9v8dpTJCbUwf-Xvg9gnE3TBnkWw8yyUKF_BTp6oOMzghVpMGYMQOYTgigMCoXkejwUyL_fxpxN6xiyfZUV7Z7N8B29HloizAdZd2HLNe3h9OebBP8Ajo4tuPBBUBE9kMewTxNZj2OLUR6zrvq5vZfDn6TV2d2SY6eGqwV6Po2bW3LVrOsEZPqk541DJgtRYJOT_tBVdK8IdzXRgIYa1W1z_mJ8h-8-mWw2i1x_hZnl6vTgX4_EKwmRJ2QmvY2u8dqUklWde17WXsTNs45TokN6UKV9i6Utl45oBTI11TGDIJkaRonQPtpu2cZ8AiVxtKSXn2Ly1thTXoTokjCB9qtIIjjbfu_o1qGhUk15yj07F6FQ9OlUZwcEGkmq0qPtKMo9lLpYpGcG36THbQkhwUOPaB25TcPTIfCtPItgfoJyGS3XJsVuiIjjeYPvU-b_f5fP_Nf8CbySznmFb9wFsd3cP7iuzlq4-hJ3Zcj6_Ouyn7W-areTC |
link.rule.ids | 315,786,790,27955,27956,41153,42222,51609 |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1NT9wwEB1RkNpeUOkHBGiZStxaV4mTtZMjXUGXlkUcFolbNPGHtIdNEA2_pH-44yQbRGkPvSSHWHaU58m88XieAY5jn-XkCxKpyqzIcidFMSGOeWJtfG6IdKezPb9Us-vs-83kZpDJCbUwf-Tvg9gnE3TBnkWw88yVKJ7BVli2CKcVTNV0zBiEyCEEVxwQCM3zeCiQ-Xsfj53QE2b5JCvaOZuzV7A9sEQ86WHdgQ1Xv4bn8yEP_gZ-MbrohgNBRfBEFsM-QWw8hi1OXcS66ur6lgavThfY3pFhpofLGjs9jopZc9us6Aue4IOaM_aVLEi1RUL-T1vRNiLc0YwHFmJYu8XV-ddvyP6zbpe96PVbuD47XUxnYjheQZgsKVrhdWyN166QpCaZ11XlZewM2zglOqQ3ZcqXWPpC2bhiAFNjHRMYsolRpCh9B5t1U7s9QCJXWUrJOTZvrS3FVagOCSNIn6o0gk_r713e9ioa5aiX3KFTMjplh05ZRHC4hqQcLOpnKZnHMhfLlIzg4_iYbSEkOKh2zT23yTl6ZL41SSLY7aEch0t1wbFboiL4vMb2ofN_v8v-_zU_ghezxfyivDi__HEALyUzoH6L9yFstnf37j0zmLb60E3d3yqz5ic |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3LTt0wEB21VELdoL4J0HYqdde65HXteEkpt9AWxAIkdtHED-kuboIgfAk_zNjJDa1oF90ki1hOlOPJnMmZGQN8TH1ZkdckCllaUVYuF3pGHPOkyvjKEKnYZ_v4RB6elz8uZhe_VfHHbPeVJDnUNIQuTW2_e2n97lT4Fly1FuxvBLvUSgr9GJ6UTG6iXCv3Jx0hxBMh5OIwQShe3WPZzN_n-NM1PeCbD7TS6ILmz2Bj5I64N4D9HB659gWsH4_q-Eu4ZczRjduEiuCfLIbsQew8hsSnGMcuY7XfwuDpwRn2V2SY_-Gixdilo2Eu3XdL-oJ7eN_jGYf6FqTWIiF_va3oOxHOaKZtDDH80cXl0dfvyF617RdDK-xXcD4_ONs_FOOmC8KUme6FV6k1Xjmdk5yVXjWNz1Nn2PIpU0H0zAs-pLnX0qYNw1oY65jWkM2MJEnFa1hru9ZtAhK5xlJBzrHRK2UpbULNSLhD7gtZJPBp9b7ry6G3Rj11UY7o1IxOHdGpdQI7K0jq0c6u65zZLTO0UuYJfJgus4UE2YNa193wmIpjSmZhsyyBNwOU0-0KpTmiy2QCn1fY3k_-72fZ-r_h72H99Nu8_nV08nMbnuZMi4a87x1Y669u3FumNX3zLq7cOz-j7nc |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+evidence-based+role+of+catecholaminergic+PET+tracers+in+Neuroblastoma.+A+systematic+review+and+a+head-to-head+comparison+with+mIBG+scintigraphy&rft.jtitle=European+journal+of+nuclear+medicine+and+molecular+imaging&rft.au=Piccardo%2C+Arnoldo&rft.au=Treglia%2C+Giorgio&rft.au=Fiz%2C+Francesco&rft.au=Bar-Sever%2C+Zvi&rft.date=2024-02-01&rft.pub=Springer+Nature+B.V&rft.issn=1619-7070&rft.eissn=1619-7089&rft.volume=51&rft.issue=3&rft.spage=756&rft.epage=767&rft_id=info:doi/10.1007%2Fs00259-023-06486-9&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1619-7070&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1619-7070&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1619-7070&client=summon |